TransDigm (TDG) director granted 518 options at $1,291.97
TransDigm Group (TDG): Director Peter Palmer reported an equity grant on Form 4.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
TransDigm Group (TDG): Director Peter Palmer reported an equity grant on Form 4. He acquired stock options covering 518 shares on Nov 4, 2025 with an exercise price of $1,291.97 per share and an expiration date of Nov 4, 2035.
The options vest at 20% per year over five years, beginning Sept 30, 2026, and are subject to the achievement of annual operating performance targets each year. Following the transaction, 518 derivative securities were beneficially owned on a direct basis.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 518 | $0.00 | $0.00 |
Footnotes (1)
- F1. These options are exercisable at 20% per year over five years beginning September 30, 2026 subject to the achievement of annual operating performance targets in each year.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did TDG disclose in this Form 4?
What is the exercise price of the options reported by TDG's director?
When do the TDG options vest and what are the conditions?
When do the reported TDG options expire?
How many derivative securities are beneficially owned after this transaction?
What is the reporting person's relationship to TDG?
What is the ownership form of the reported options?
AI-generated analysis. How Rhea-AI works. Not financial advice.